论文部分内容阅读
目的探讨消化系统恶性肿瘤组织中生长抑素受体亚型SSTR2、SSTR5 mRNA表达状况及其与肿瘤的相关性。方法收集消化系肿瘤标本共66例,均经手术及病理证实。男性44例,女性22例,PCR扩增SSTR2、SSTR5 mRNA,并进行琼脂糖凝胶电泳,测其OD值并进行分析。结果不同肿瘤SSTR2 mRNA的表达频率不同,肝癌组织明显高于胃癌、结肠癌和胰腺癌(P<0.05),胃癌、结肠癌和胰腺癌之间表达无明显差异。肝癌癌组织与癌旁组织之间表达水平无明显差异,但与正常组织表达水平有显著差异(P<0.05);胃癌、结肠癌和胰腺癌癌组织与癌旁组织、正常组织之间表达无显著性差异(P>0.05)。SSTR5 mRNA的表达频率和表达水平在消化系肿瘤中差异不显著(P>0.05)。结论(1)胃癌、结肠癌、肝癌及胰腺癌组织中有SSTR2、5亚型表达,以SSTR2亚型为主。(2)SSTR2亚型在胃癌、结肠癌、肝癌及胰腺癌的表达频率及表达水平不同。在肝癌中呈高表达,在胃癌、结肠癌及胰腺癌中表达水平较低。(3)SSTR2、5亚型的表达频率、表达水平与癌组织分化程度、有无淋巴结转移密切相关,结肠癌与肿瘤分期有密切关系。(4)SSTR2亚型鉴定对胃癌、结肠癌、肝癌及胰腺癌是否适合生长抑素治疗具有一定指导意义。
Objective To investigate the expression of SSTR2 and SSTR5 mRNA in the malignant tumors of the digestive system and their correlation with tumors. Methods A total of 66 cases of digestive tumors were collected and confirmed by operation and pathology. There were 44 males and 22 females. The SSTR2 and SSTR5 mRNAs were amplified by PCR and subjected to agarose gel electrophoresis. The OD values were measured and analyzed. Results The expression of SSTR2 mRNA was different in different tumors. The liver cancer tissue was significantly higher than that in gastric cancer, colon cancer and pancreatic cancer (P<0.05). There was no significant difference between gastric cancer, colon cancer and pancreatic cancer. There was no significant difference in the expression level between hepatocellular carcinoma tissues and adjacent tissues, but there was a significant difference with normal tissue expression levels (P<0.05). No expression was found between gastric cancer, colon cancer and pancreatic cancer tissues, adjacent tissues and normal tissues. Significant difference (P>0.05). There was no significant difference in the expression frequency and expression level of SSTR5 mRNA in the digestive system tumors (P>0.05). Conclusion (1) SSTR2, 5 subtypes are expressed in gastric cancer, colon cancer, liver cancer, and pancreatic cancer tissues, and SSTR2 subtype is the major one. (2) SSTR2 subtypes have different expression frequencies and expression levels in gastric cancer, colon cancer, liver cancer, and pancreatic cancer. It is highly expressed in liver cancer and is low in gastric cancer, colon cancer, and pancreatic cancer. (3) The expression frequency and expression level of SSTR2, 5 subtypes are closely related to the degree of differentiation of cancer tissues and lymph node metastasis. Colon cancer is closely related to tumor stage. (4) SSTR2 subtype identification has certain guiding significance for the suitability of somatostatin therapy for gastric cancer, colon cancer, liver cancer and pancreatic cancer.